Glenmark Pharmaceuticals Limited has unveiled top-line results from its Phase III clinical trial with favipiravir, indicating that early treatment with the antiviral improves clinical outcomes for mild-to-moderate patients and potentially prevent their condition from worsening to acute respiratory distress syndrome or death.
Favipriravir has already received emergency use authorization (EUA) in India for the treatment of mild to moderate COVID-19, where it...






